<DOC>
	<DOCNO>NCT02608216</DOCNO>
	<brief_summary>In study positron emission tomography ( PET/CT ) image use evaluate proliferative activity sit metastatic disease use investigational radiotracer [ 18F ] fluorothymidine ( FLT ) .</brief_summary>
	<brief_title>18FFLT PET/CT Rb+ Metastatic Breast Cancer</brief_title>
	<detailed_description>This protocol design develop relationship parameter determine image biomarker study one use determination therapeutic response combine CDK4 Inhibitor chemotherapy regimen . Imaging occur prior start therapy separate therapeutic protocol UPCC 06115 . Patients may undergo second FLT PET/CT scan follow 3-day run ribociclib ( LEE011 ) ( day -6 -4 ) third FLT PET/CT scan cycle 1 day 12 follow two treatment weekly Paclitaxel compare change FLT uptake measure .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . At least 18 year age 2 . History histologically cytologically confirm breast cancer , ER , PR HER2 status allow long express Rb protein . 3 . At least one site metastatic breast cancer outside liver bone identify standard imaging ( e.g . CT , MRI , FDG PET/CT , ultrasound , xray ) 4 . Participants must inform investigational nature study provide write informed consent accordance institutional federal guideline prior studyspecific procedure . 5 . Patients must candidate receive treatment therapeutic trial UPCC06115 , Phase I study ribociclib ( LEE011 ) weekly paclitaxel . 1 . Females pregnant time screen eligible study , urine pregnancy test perform screen woman childbearing potential . 2 . Inability tolerate image procedure opinion investigator treat physician 3 . Serious unstable medical psychological condition , opinion investigator , would compromise subject 's safety successful participation study . 4 . Ineligible therapeutic trial UPCC 06115</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>